GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Actinium Pharmaceuticals Inc (AMEX:ATNM) » Definitions » Price-to-Free-Cash-Flow

ATNM (Actinium Pharmaceuticals) Price-to-Free-Cash-Flow : N/A (As of Dec. 13, 2024)


View and export this data going back to 2007. Start your Free Trial

What is Actinium Pharmaceuticals Price-to-Free-Cash-Flow?

As of today (2024-12-13), Actinium Pharmaceuticals's share price is $1.25. Actinium Pharmaceuticals's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Sep. 2024 was $-1.19. Hence, Actinium Pharmaceuticals's Price-to-Free-Cash-Flow Ratio for today is N/A.

The historical rank and industry rank for Actinium Pharmaceuticals's Price-to-Free-Cash-Flow or its related term are showing as below:

During the past 13 years, Actinium Pharmaceuticals's highest Price-to-Free-Cash-Flow Ratio was 242.31. The lowest was 11.75. And the median was 25.19.

ATNM's Price-to-Free-Cash-Flow is not ranked *
in the Biotechnology industry.
Industry Median: 35.545
* Ranked among companies with meaningful Price-to-Free-Cash-Flow only.

Actinium Pharmaceuticals's Free Cash Flow per Share for the three months ended in Sep. 2024 was $-0.39. Its Free Cash Flow per Share for the trailing twelve months (TTM) ended in was $-1.19.

During the past 3 years, the average Free Cash Flow per Share Growth Rate was 0.30% per year.

During the past 13 years, Actinium Pharmaceuticals's highest 3-Year average Free Cash Flow per Share Growth Rate was 53.00% per year. The lowest was -1303.30% per year. And the median was 20.75% per year.


Actinium Pharmaceuticals Price-to-Free-Cash-Flow Historical Data

The historical data trend for Actinium Pharmaceuticals's Price-to-Free-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Actinium Pharmaceuticals Price-to-Free-Cash-Flow Chart

Actinium Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Free-Cash-Flow
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - 31.05 -

Actinium Pharmaceuticals Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Price-to-Free-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Actinium Pharmaceuticals's Price-to-Free-Cash-Flow

For the Biotechnology subindustry, Actinium Pharmaceuticals's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Actinium Pharmaceuticals's Price-to-Free-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Actinium Pharmaceuticals's Price-to-Free-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Actinium Pharmaceuticals's Price-to-Free-Cash-Flow falls into.



Actinium Pharmaceuticals Price-to-Free-Cash-Flow Calculation

Actinium Pharmaceuticals's Price-to-Free-Cash-Flow ratio for today is calculated as

Price-to-Free-Cash-Flow Ratio=Share Price/ Free Cash Flow per Share (TTM)
=1.25/-1.188
=N/A

Actinium Pharmaceuticals's Share Price of today is $1.25.
Actinium Pharmaceuticals's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.19.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

Price-to-Free-Cash-Flow Ratio=Market Cap/Free Cash Flow

Actinium Pharmaceuticals  (AMEX:ATNM) Price-to-Free-Cash-Flow Explanation

Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.

In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.


Be Aware

In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.


Actinium Pharmaceuticals Price-to-Free-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Actinium Pharmaceuticals's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


Actinium Pharmaceuticals Business Description

Traded in Other Exchanges
Address
100 Park Avenue, 23rd Floor, New York, NY, USA, 10017
Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of radiotherapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest to kill those cells safely and effectively. Its product candidates are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia.
Executives
Sandesh Seth director 300 E 93RD STREET, #20-B, NEW YORK NY 10128
Steve O'loughlin officer: VP, Finance and Corporate Dev. 955 HARTMAN RUN ROAD, MORGANTOWN WV 26507
Dale L. Ludwig officer: Chief Scientific Officer 21 FERNWOOD ROAD, ROCKAWAY NJ 07866-2028
Jeffrey W. Chell director 521 MANDALAY AVENUE #708, CLEARWATER BEACH FL 33767
Ajit Shetty director 643 ZEEDIJK, KNOKKE C9 8300
Anil Kapur officer: Chief Commercial Officer 275 MADISON AVE, SUITE 702, NEW YORK NY 10016
Nitya G. Ray officer: Executive Vice President 14 BAYBURY COURT, EAST HANOVER NJ 07936
Mark Stanley Berger officer: Chief Medical Officer 140 RIVERSIDE DRIVE, APT. 9K, NEW YORK NY 10024
Memorial Sloan-kettering Cancer Center 10 percent owner 1275 YORK AVE., NEW YORK NY 10065
Sergio Traversa director 138 CANTERBURY LN, BLUE BELL PA 19422
C. David Nicholson, director 103 CHILDS ROAD, BASKIN RIDGE NJ 07092
Kaushik J Dave director, officer: President and CEO 4 WATER STREET, EDISON NJ 08820
Richard I Steinhart director 125 ELM STREET, NEW CANAAN CT 06840
Ahlb Holdings, Llc 10 percent owner C/O MSKCC, 1275 YORK AVE., NEW YORK NY 10065
Actinium Holdings, Ltd. 10 percent owner C/O /O STERLING MANAGEMENT, LTD., P.O. BOX HM 29, HAMILTON HM CX D0 00000

Actinium Pharmaceuticals Headlines

From GuruFocus